Abstract:Background Glioma represents the predominant primary malignant brain tumor. For several years, molecular profiling has been instrumental in the management and therapeutic stratification of glioma, providing a deeper understanding of its biological complexity. Accumulating evidence unveils the putative involvement of zinc finger proteins (ZNFs) in cancer. This study aimed to elucidate the role and significance of ZNF207 in glioma. Methods Utilizing online data such as The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), the Genotype‐Tissue Expression (GTEx) project, the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and the Human Protein Atlas (HPA) databases, in conjunction with bioinformatics methodologies including GO, KEGG, GSEA, CIBERSORT immune cell infiltration estimation, and protein–protein interaction (PPI) analysis, enabled a comprehensive exploration of ZNF207's involvement in gliomagenesis. Immunohistochemistry and RT‐PCR techniques were employed to validate the expression level of ZNF207 in glioma samples. Subsequently, the biological effects of ZNF207 on glioma cells were explored through in vitro assays. Results Our results demonstrate elevated expression of ZNF207 in gliomas, correlating with unfavorable patient outcomes. Stratification analyses were used to delineate the prognostic efficacy of ZNF207 in glioma with different clinicopathological characteristics. Immunocorrelation analysis revealed a significant association between ZNF207 expression and the infiltration levels of T helper cells, macrophages, and natural killer (NK) cells. Utilizing ZNF207 expression and clinical features, we constructed an OS prediction model and displayed well discrimination with a C‐index of 0.861. Moreover, the strategic silencing of ZNF207 attenuated glioma cell advancement, evidenced by diminished cellular proliferation, weakened cell tumorigenesis, augmented apoptotic activity, and curtailed migratory capacity alongside the inhibition of the epithelial‐mesenchymal transition (EMT) pathway. Conclusions ZNF207 may identify as a prospective biomarker and therapeutic candidate for glioma prevention, providing valuable insights into understanding glioma pathogenesis and treatment strategies.

Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial–mesenchymal transition in vitro and predicts poor prognosis in glioma

Long Non‑coding RNA LINC00473/miR‑195‑5p Promotes Glioma Progression Via YAP1‑TEAD1‑Hippo Signaling.

A Long Noncoding Rna Zeb1-As1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma

ZNF395 Facilitates Macrophage Polarization and Impacts the Prognosis of Glioma.

Upregulation of the Long Non-Coding RNA SNHG1 Predicts Poor Prognosis, Promotes Cell Proliferation and Invasion, and Reduces Apoptosis in Glioma.

Retraction Note: Upregulation of Long Noncoding RNA ZEB1-AS1 Promotes Tumor Metastasis and Predicts Poor Prognosis in Hepatocellular Carcinoma

The Long Noncoding Rna Zfas1 Promotes The Progression Of Glioma By Regulating The Mir-150-5p/Plp2 Axis

Long Non-Coding RNA HOTAIRM1 Promotes Proliferation and Inhibits Apoptosis of Glioma Cells by Regulating the Mir-873-5p/zeb2 Axis

Zinc finger Protein207 orchestrates glioma migration through regulation of epithelial‐mesenchymal transition

Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients

Long Noncoding RNA Lncherg Promotes Cell Proliferation, Migration and Invasion in Glioblastoma

Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma

Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma

ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma

Long Non-coding RNA MALAT1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124

Long Non-Coding RNA LINC01503 Predicts Worse Prognosis in Glioma and Promotes Tumorigenesis and Progression Through Activation of Wnt/β-catenin Signaling.

Long Noncoding RNA ZEB1-AS1 Predicts an Unfavorable Prognosis of Non-Small Lung Cancer and Regulates Epithelial to Mesenchymal Transition Through Reducing ZEB1 Expression.

Long Non‐coding RNA SNHG1 Stimulates Ovarian Cancer Progression by Modulating Expression of Mir‐454 and ZEB1

Dysregulation of LINC00324 promotes poor prognosis in patients with glioma

Long Noncoding RNA ZEB1-AS1 Downregulates miR-23a, Promotes Tumor Progression, and Predicts the Survival of Oral Squamous Cell Carcinoma Patients

MicroRNA‑301a/ZNRF3/wnt/β‑catenin signal regulatory crosstalk mediates glioma progression